Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
Swiss multinational firm Nestlé and Aimmune Therapeutics, Inc., a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies in the US, have entered into a definitive agreement pursuant to which Nestlé Health Science (NHSc) would acquire Aimmune.
Aimmune’s Palforzia is the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts, including anaphylaxis, in children aged 4 through 17.
The acquisition is an extension of NHSc’s food allergy portfolio, creating a broader spectrum of solutions for children living with food allergies.
NHSc currently has a total investment in Aimmune of $473 million, an approximate 25.6% equity ownership stake. Around 19.6% is voting common stock and the balance non-voting preferred stock. NHSc made its initial investment of $145 million in Aimmune in November 2016, followed by further investments of $30 million in February 2018, $98 million in November 2018 and $200 million in January 2020.
The acquisition is expected to be accretive to Nestlé’s organic growth in 2021 and accretive to cash earnings by 2022/23.